HomeACADEMIA
ACADEMIA

Oncologist Hails Tagrisso Approval for 1st-Line Lung Cancer Treatment
(Sep.14.2018)

Yuichiro Ohe, Chief, Department of Thoracic Oncology, National Cancer Center
The use of Tagrisso (osimertinib) in front-line treatment would bring the biggest benefits to patients with EGFR-mutated lung cancer, Yuichiro Ohe, a prominent oncologist at the National Cancer Center (NCC), said on September 13, welcoming the first-line nod given to the AstraZeneca drug in Japan last month ...
(LOG IN FOR FULL STORY)

News Calendar